CJC-1295 vs Sermorelin: Half-Life, Evidence and Legal Access Compared

Feature	Sermorelin	CJC-1295 (with DAC)
Chemical identity	GHRH(1-29), truncated native hormone	Engineered 30-amino-acid GHRH analog with Drug Affinity Complex
Developer	Serono (now EMD Serono)	ConjuChem Biotechnologies
Plasma half-life	10-20 minutes	5.8-8.1 days (Teichman 2006)
GH release pattern	Short pulse mimicking natural GHRH rhythm	Sustained elevation with raised trough levels
IGF-1 elevation duration	Hours after each administration	9-11 days after single injection
Highest evidence tier	FDA-approved (1990/1997, withdrawn 2008 for commercial reasons)	Phase 2 (halted 2006 after participant death)
FDA status (2026)	Compoundable under 503A (prior approval history)	PCAC rejected December 2024, no compounding pathway
WADA status	S2 (Peptide Hormones)	S2 (Peptide Hormones)
UK status	Not controlled, no approved product, RUO available	Not controlled, no approved product, RUO available
Australia (TGA)	Schedule 4 (prescription only)	Schedule 4 (prescription only)

Sermorelin is a truncated copy of the body’s own GHRH – the first 29 amino acids of the 44-amino-acid native hormone – and it behaves accordingly, clearing from plasma within 10-20 minutes and producing a short, discrete GH pulse that closely mimics the body’s natural secretory rhythm. CJC-1295 with DAC (Drug Affinity Complex) covalently binds to circulating albumin through a reactive chemical group called maleimidopropionic acid, extending its plasma half-life to 5.8-8.1 days as established in the Teichman 2006 study published in the Journal of Clinical Endocrinology and Metabolism.

This is not a minor pharmacokinetic difference. Sermorelin produces GH pulses that rise and fall within hours, preserving the pulsatile pattern that characterises healthy endogenous GH secretion. CJC-1295 with DAC produces what researchers describe as an elevated mean 24-hour GH pattern – raised trough levels alongside maintained pulses – documented by Ionescu and Frohman in 2006. Whether this sustained elevation pattern carries advantages or disadvantages over natural pulsatility remains an open question without long-term comparative data.

The bottom line: Sermorelin produces short physiological GH pulses lasting minutes, while CJC-1295 with DAC produces sustained GH elevation lasting days – two fundamentally different approaches to stimulating the same pituitary receptor.

Sermorelin has the stronger evidence base by a considerable margin, having completed the full FDA approval pathway for two separate indications. Geref Diagnostic (NDA 19-863) was approved in December 1990 for evaluating pituitary GH secretion capacity, and Geref (NDA 20-443) was approved in September 1997 for treating idiopathic growth hormone deficiency in children with growth failure. Both approvals required Phase 3 clinical trial data meeting FDA standards of the era.

EMD Serono voluntarily discontinued Geref in 2008 and requested withdrawal of both NDAs, which the FDA granted effective June 18, 2009. Critically, the FDA published a determination in the Federal Register on March 4, 2013, confirming that Geref was not withdrawn for reasons of safety or effectiveness – the discontinuation was a commercial decision. This determination has direct regulatory consequences: it means sermorelin remains eligible for compounding under 503A pharmacy law, a distinction that separates it from most other GH-axis peptides.

CJC-1295 evidence profile

CJC-1295’s clinical development is limited to two published trials by Teichman and colleagues. The Phase 1 programme consisted of two randomised, double-blind, placebo-controlled ascending-dose studies in healthy adults aged 21-61. Single subcutaneous doses ranging from 1 to 30 mcg/kg produced dose-dependent GH increases of 2- to 10-fold above baseline. IGF-1 levels rose 1.5- to 3-fold and remained elevated for 9-11 days after a single injection. After multiple doses, IGF-1 stayed above baseline for up to 28 days.

ConjuChem then initiated a Phase 2 study for HIV-associated lipodystrophy, enrolling 192 participants across sites in North and South America. The trial was halted on July 17, 2006, after the death of a participant at an Argentinian study site. The attending physician concluded the most likely cause was asymptomatic coronary artery disease with plaque rupture and occlusion, unrelated to the study drug. ConjuChem terminated the programme as a precaution and never resumed development. For a deeper analysis of the CJC-1295 evidence base and safety profile, see the CJC-1295 compound guide.

The bottom line: Sermorelin reached FDA approval and was withdrawn for commercial reasons after nearly two decades of clinical use, while CJC-1295’s development ended at Phase 2 after a participant death and the compound has never been approved in any country.

The regulatory gap between these two compounds is the single most consequential practical difference for anyone evaluating them in 2026. Sermorelin’s prior FDA approval history – and the 2013 Federal Register determination that it was not withdrawn for safety or efficacy reasons – means it can be legally compounded under 503A pharmacy frameworks for patients with valid prescriptions. This is why sermorelin remains available through licensed compounding pharmacies across the United States when most other GH-axis peptides have lost access.

CJC-1295 occupies a far more precarious position. After being placed on FDA Category 2 in September 2023, it was removed in September 2024 when nominators withdrew their submissions. The FDA then referred all CJC-1295 variants – free base, acetate, DAC free base, DAC acetate, and DAC trifluoroacetate – to the PCAC for evaluation. On December 4, 2024, the committee voted against including any CJC-1295 variant on the 503A Bulks List, citing cardiac side effects, immunogenicity concerns, and insufficient clinical evidence.

Whether CJC-1295 was included in the February 2026 announcement by HHS Secretary Kennedy regarding reclassification of approximately 14 peptides remains disputed across sources. Even if included, the December 2024 PCAC rejection represents a significant procedural barrier. For the full reclassification timeline, see the RFK reclassification tracker.

Jurisdiction	Sermorelin	CJC-1295
United States	Compoundable under 503A with prescription	PCAC rejected (Dec 2024), no authorised compounding pathway
United Kingdom	Not controlled, no approved product, RUO available	Not controlled, no approved product, RUO available
Australia	Schedule 4 (prescription only)	Schedule 4 (prescription only)
WADA	S2 – prohibited at all times	S2 – prohibited at all times

For country-specific legal frameworks in detail, see the jurisdiction guides for the United States, United Kingdom, and Australia.

The bottom line: Sermorelin is the only GHRH analog with a legitimate US compounding pathway in 2026, making the regulatory comparison the most decisive practical difference between these two compounds.

Sermorelin has the longest safety track record of any GH-axis peptide, spanning from its original clinical trials through nearly two decades of marketed use (1990-2008) and continued compounding pharmacy use since. Its established adverse effects are mild: injection site reactions, facial flushing, headache, and occasional nausea. The FDA’s explicit determination that it was not withdrawn for safety reasons provides a level of regulatory confidence that no other GH secretagogue peptide can claim.

CJC-1295’s safety dataset is considerably thinner. The Phase 1 data from the Teichman trials reported no serious adverse reactions at doses up to 60 mcg/kg. However, the FDA’s December 2024 PCAC briefing documents cited nonclinical findings including reduced food and water intake, softer stools, decreased activity, vomiting, reduced haemoglobin, increased cholesterol, injection site inflammation and necrosis, and DNA damage in pituitary cells. These nonclinical signals – particularly the pituitary DNA damage finding – were among the concerns cited when the committee voted against 503A inclusion.

The sustained GH elevation produced by CJC-1295 with DAC raises theoretical questions that sermorelin’s pulsatile pattern does not. Long-term supraphysiological GH and IGF-1 levels are associated with increased cardiovascular risk, glucose dysregulation, and theoretical cancer risk based on GH biology. Because CJC-1295’s half-life extends to nearly a week, course-correcting in the event of adverse effects takes considerably longer than with sermorelin, where effects resolve within hours of the last administration.

The bottom line: Sermorelin has nearly three decades of human safety data and an explicit FDA safety determination, while CJC-1295’s safety profile rests on limited Phase 1 data and carries unresolved nonclinical concerns that contributed to its PCAC rejection.

The comparison between these two GHRH analogs is less balanced than marketing material from peptide clinics might suggest. In 2026, the decision framework is shaped more by regulatory reality than by pharmacological preference.

Sermorelin is the clear choice for anyone prioritising legal access through a licensed prescriber and compounding pharmacy. Its prior FDA approval gives it a regulatory standing that CJC-1295 simply does not have. Its short half-life means GH stimulation closely mimics the body’s natural rhythm, and any adverse effects resolve quickly after discontinuation. The trade-off is that its brief duration of action requires more frequent administration.

CJC-1295 with DAC offers the theoretical advantage of less frequent administration and sustained IGF-1 elevation. However, it currently has no authorised compounding pathway in the United States, its clinical development was halted at Phase 2, and the PCAC cited specific safety concerns when rejecting its nomination. Anyone sourcing CJC-1295 in 2026 is obtaining it outside regulated pharmacy channels, which introduces product quality risks that are impossible to fully mitigate. For guidance on assessing research peptide quality, see the vendor evaluation guide and the COA reading guide.

It is also worth noting that CJC-1295 is most commonly used as part of a stack with ipamorelin – the CJC-1295/ipamorelin combination is the dominant GH secretagogue protocol in clinical and community settings. Ipamorelin faces its own PCAC rejection (October 2024), meaning the entire stack currently sits outside authorised compounding frameworks. For broader context on the GH secretagogue landscape, see the sermorelin compound guide, which covers its position relative to other options including ipamorelin and MK-677.

Is CJC-1295 without DAC basically the same as sermorelin?

They are similar but not identical. CJC-1295 without DAC (Modified GRF 1-29) has a comparable half-life of roughly 30 minutes and produces a similar pulsatile GH pattern. The amino acid sequence differs – sermorelin is a direct truncation of native GHRH while Mod GRF 1-29 includes four amino acid substitutions at positions 2, 8, 15, and 27 for improved stability. However, from a regulatory standpoint they are in completely different positions: sermorelin’s prior FDA approval history grants it compounding eligibility that Mod GRF 1-29 does not have.

Why was CJC-1295 rejected by the PCAC when the participant death was deemed unrelated?

The PCAC rejection in December 2024 was not based on the 2006 participant death. The committee cited three distinct concerns: cardiac side effects identified in nonclinical studies, immunogenicity (the potential for the body to develop antibodies against the compound), and insufficient clinical evidence to establish a positive benefit-risk profile for compounding. The nonclinical finding of DNA damage in pituitary cells was particularly notable. The category system and PCAC process are explained in the regulatory section above.

Could the Kennedy reclassification restore CJC-1295 to compounding?

The February 2026 HHS announcement indicated that roughly 14 of the 19 previously restricted peptides would move back toward compounding eligibility, but whether CJC-1295 is among them remains disputed across sources. Even if included in the directive, the existing PCAC vote against inclusion represents a formal advisory committee recommendation that the FDA would need to override or revisit. The full timeline and status of each compound is covered in the reclassification tracker linked in the regulatory section above.

How does tesamorelin fit into this comparison?

Tesamorelin (brand name Egrifta) is the only GHRH analog with current full FDA approval – specifically for HIV-associated lipodystrophy. It has Phase 3 RCT evidence in that indication and represents the regulatory gold standard in this compound class. However, it is only approved for a single narrow indication and is priced accordingly. In the GHRH analog landscape, tesamorelin sits above both sermorelin and CJC-1295 in terms of current regulatory standing and evidence quality, though its clinical accessibility for off-label GH optimisation remains limited.